SignaBlok Announces Notice of Patent Allowance on TREM-1 Peptide Therapeutics for Sepsis and Cancer

SHREWSBURY, Mass. - July 1, 2013 - PRLog -- Shrewsbury, MA, July 1, 2013 – SignaBlok, Inc. today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application covering TREM-1 receptor-specific peptides for sepsis, cancer and other inflammation-associated indications. The allowed claims cover both product composition and treatment methods.

This application is the first patent application to issue, which broadly covers the Company's proprietary, first-in-class peptides, known as the SCHOOL peptides. The peptides target TREM-1, a specific receptor that serves as an inflammation amplifier and is critically involved in the pathogenesis of various cancers, sepsis, rheumatoid arthritis, and other inflammation-associated diseases.

"We are pleased that the USPTO has allowed this patent application, which will substantively expand the coverage of SignaBlok's intellectual property estate," said Alexander Sigalov, Ph.D., President, Inventor and Founder of SignaBlok. "SignaBlok continues to develop novel intellectual property in the area of the SCHOOL technology that allows to block specific receptors in a new, ligand-independent manner. We have recently succeeded in the animal proof-of-concept testing of the SCHOOL technology in sepsis and lung cancer. Accordingly, we plan to consolidate key intellectual property required to develop and commercialize first-in-class therapies for these and other serious diseases with unmet clinical needs".

The new patent is expected to issue in the next few months.

About SignaBlok

SignaBlok is developing a new class of therapies – SCHOOL peptides, the innovative modulatory peptides that can be rationally designed for nearly any cell surface receptor and have broad potential to treat and prevent a wide range of serious diseases with unmet clinical needs. SignaBlok is also developing a nanotechnology that enables targeted delivery of SCHOOL peptides and other therapies and/or imaging agents, aiming to improve efficacy, reduce dose, and allow image-guided therapy. Additional information about SignaBlok is available at www.signablok.com.

SignaBlok Forward-Looking Statement

Various statements in this release concerning SignaBlok's future expectations, plans and prospects, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. SignaBlok's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although SignaBlok's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by SignaBlok. Readers are cautioned not to rely on these forward-looking statements.